Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00200538 |
Recruitment Status :
Completed
First Posted : September 20, 2005
Last Update Posted : May 3, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dementia | Drug: memantine | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 52 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients |
Study Start Date : | September 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with FTD based on the criteria defined by the Lund and Manchester groups' consensus statement (revised in 1998), whose disease has been progressing during the last year.
- MMSE score of 19 or higher
- Men and women aged 45 to 75 years
- Without speech, visuospatial, or episodic memory impairments
Exclusion Criteria:
- Age > 76 years
- Illiterate or misunderstanding patients
- Patients with cancer, heart disease, lung disease, kidney disease (creatinine > 200 mg/dL), or epilepsy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00200538
France | |
Martine Vercelletto | |
Nantes, France, 44093 |
Study Director: | Martine Vercelletto, MD | Centre de la Mémoire, Clinique Neurologique CHU Nord Nantes 44093 France; mvercelletto@chu-nantes.fr | |
Principal Investigator: | Lucette Lacomblez, MD | Federation de Neurologie AP-HP Paris 75 013 France; lucette.lacomblez@psl.ap-hop-paris.fr | |
Principal Investigator: | Bruno Dubois, MD | Centre du Langage et de Neuropsychologie AP-HP Paris 75013 France; b.dubois@psl.ap-hop-paris.fr | |
Principal Investigator: | Anne Sophie Rigaud, MD | Hôpital Broca, Paris 75 France; anne-sophie.rigaud@brc.ap-hop-paris.fr | |
Principal Investigator: | Jean-Francois Dartigues, MD | Hôpital Pellegrin Bordeaux 33 076 France; jean-francois.dartigues@u.bordeaux2.fr | |
Principal Investigator: | Sophie Auriacombe, MD | Hôpital Pellegrin Bordeaux 33 076 France ; sophie.auriacombe@u.bordeaux.fr | |
Principal Investigator: | Philippe Couratier, MD | Hôpital Dupuytren, Limoges 87000 France; philippe.couratier@unilim.fr | |
Principal Investigator: | Jacques Touchon, MD | Hôpital Gui de Chaulliac, Montpellier 34 295 France; jacques.touchon@wanadoo.fr | |
Principal Investigator: | Matthieu Ceccaldi, MD | Hôpital de la Timone Marseille 13 005 France; mceccaldi@ap-hm.fr | |
Principal Investigator: | Mira Didic, MD | Hôpital de la Timone Marseille 13005 France; mira.didic@medecine.univ-mrs.fr | |
Principal Investigator: | Serge Bakchine, MD | Hôpital Maison Blanche, Reims 51 092 France; sbakchine@chu-reims.fr | |
Principal Investigator: | Bernard-Francois Michel, MD | Hôpital Sainte Marguerite, 13009 France; bmichel@ap-hm.fr | |
Principal Investigator: | Catherine Thomas-Anterion, MD | Hôpital Bellevue Saint Etienne, 42 000 France; catherine.thomas@chu-st-etienne.fr | |
Principal Investigator: | Bernard Laurent, MD | Hôpital Bellevue Saint Etienne 42 000 France; bernard.laurent@univ-st-etienne.fr | |
Principal Investigator: | Francois Sellal, MD | Hôpital Civil Strasbourg 67000 France; francois.sellal@chru-strasbourg.fr | |
Principal Investigator: | Serge Belliard, MD | Hôpital Pontchaillou Rennes 35 000, France; serge.belliard@chu-rennes.fr | |
Principal Investigator: | Herve Allain, MD | Service de Pharmacologie, CHU de Rennes 35 000 France ; Herve.allain@univ-rennes1.fr | |
Principal Investigator: | Michele Puel, MD | Hôpital Purpan, Toulouse 31059 France; PUEL.M@chu-toulouse.fr | |
Principal Investigator: | Jean-Francois Demonet, MD | Clinique Neurologique CHU Purpan Toulouse 31059 France; demonet@toulouse.inserm.fr | |
Principal Investigator: | Marie Sarazin, MD | Centre du Langage et de la Mémoire, Hôpital de la Salpétriére AP-HP Paris 75013 France |
ClinicalTrials.gov Identifier: | NCT00200538 |
Other Study ID Numbers: |
BRD 05/1-E |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | May 3, 2013 |
Last Verified: | January 2005 |
frontotemporal dementia Mémantine Patients with frontotemporal dementia |
Dementia Frontotemporal Dementia Aphasia, Primary Progressive Pick Disease of the Brain Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders Mental Disorders Neurodegenerative Diseases Frontotemporal Lobar Degeneration TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Aphasia |
Speech Disorders Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Memantine Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents |